// App-Quantinova.ai

OP0237 : THROMBOEMBOLIC SAFETY PROFILE OF TOFACITINIB AND BARICITINIB: AN ANALYSIS OF WHO VIGIBASE

Researchers

Presenter

  • E. Vallejo-Yage

Principal Investigators

  • S. Weiler

  • A. M. Burden

Medical Centers

  • ETH Zurich, Department of Chemistry and Applied Biosciences, Zürich, Switzerland

  • National Poisons Information Centre, Tox Info Suisse, Associated Institute of the University of Zurich, Zurich, Switzerland

Locations

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Deep vein thrombosis

  • Pulmonary embolism

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

  • Tasocitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved